A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma

Moon Jin Kim, Se Hoon Park, Jae Lyun Lee, Se Hoon Lee, Su Jin Lee, Ho Yeong Lim

Research output: Contribution to journalArticlepeer-review

13 Scopus citations

Abstract

Background: The efficacy and/or tolerability of pazopanib in patients with metastatic renal cell carcinoma (mRCC) have been found to differ in Western and Asian populations. This retrospective multicenter study analyzed the results of first-line pazopanib treatment in 93 consecutive patients with mRCC who were treated at the medical oncology departments of three tertiary cancer centers in Seoul, Korea. Methods: The decision to administer pazopanib as first-line therapy was at the discretion of the treating physician in all patients with mRCC. Patients enrolled in clinical trials were excluded to ensure that the results would reflect real-world outcomes representative of daily clinical settings. All patients received 800 mg/day pazopanib. Outcomes included response rate, progression-free survival (PFS), overall survival (OS), and safety. Results: The 93 patients included72 (77 %) male and 21 (23 %) female individuals, of median age 65 years (range, 19-84 years). The median number of metastatic sites per patient was two (range, 1-5), with the lungs being the most frequently involved site. Most patients had favorable (n = 46) or intermediate (n = 36) risk as determined by Memorial Sloan Kettering Cancer Center criteria. Pazopanib was generally welltolerated: the major hematologic adverse effect was grade 1/2 anemia (14 %); and the most frequently observed non-hematologic toxicity was grade 1/2 mucositis (22 %), followed by hair discoloration and hypertension. Of the 93 patients, three (3 %) showed complete response, 52 (56 %) showed partial response, and 21 (23 %) showed stable disease, making the objective response rate 59 % and the disease control rate 82 %. At a median follow-up of 21 months, the estimated median PFS and OS were 12.2 months (95 % confidence interval, 7.1-17.4 months) and 21.9 months (95 % confidence interval, 12.9-30.9 months), respectively. Conclusions: In this retrospective study, first-line therapy with pazopanib demonstrated clinically relevant efficacy and tolerability in unselected real-world Korean patients with mRCC. OS and PFS of these Korean patients were similar to those reported in phase III trials.

Original languageEnglish
Article number46
JournalBMC Urology
Volume16
Issue number1
DOIs
StatePublished - 2 Aug 2016

Bibliographical note

Publisher Copyright:
© 2016 Kim et al.

Keywords

  • Clear-cell carcinoma
  • First-line
  • Pazopanib
  • Renal cell carcinoma

Fingerprint

Dive into the research topics of 'A Korean multi-center, real-world, retrospective study of first-line pazopanib in unselected patients with metastatic renal clear-cell carcinoma'. Together they form a unique fingerprint.

Cite this